CN109091584A - 一种消肿止痛药膏及其制备方法 - Google Patents
一种消肿止痛药膏及其制备方法 Download PDFInfo
- Publication number
- CN109091584A CN109091584A CN201811268843.4A CN201811268843A CN109091584A CN 109091584 A CN109091584 A CN 109091584A CN 201811268843 A CN201811268843 A CN 201811268843A CN 109091584 A CN109091584 A CN 109091584A
- Authority
- CN
- China
- Prior art keywords
- parts
- swelling
- pain relieving
- borneol
- iodine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 46
- 230000036407 pain Effects 0.000 title claims abstract description 46
- 239000002674 ointment Substances 0.000 title claims abstract description 43
- 230000008961 swelling Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 56
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 41
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 40
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229940116229 borneol Drugs 0.000 claims abstract description 40
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 40
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229940098465 tincture Drugs 0.000 claims abstract description 37
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960003276 erythromycin Drugs 0.000 claims abstract description 22
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003128 mupirocin Drugs 0.000 claims abstract description 21
- 229930187697 mupirocin Natural products 0.000 claims abstract description 21
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims abstract description 21
- -1 bagodryl hydrochloride Chemical compound 0.000 claims abstract description 20
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 19
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 19
- 239000011630 iodine Substances 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 19
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960001309 procaine hydrochloride Drugs 0.000 claims abstract description 15
- 229940099259 vaseline Drugs 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 241000717739 Boswellia sacra Species 0.000 claims description 7
- 239000004863 Frankincense Substances 0.000 claims description 7
- 238000000227 grinding Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 240000007311 Commiphora myrrha Species 0.000 claims description 6
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 6
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 6
- 229960004919 procaine Drugs 0.000 claims 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 2
- 241000205585 Aquilegia canadensis Species 0.000 claims 1
- 241000345998 Calamus manan Species 0.000 claims 1
- 235000012950 rattan cane Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 206010000269 abscess Diseases 0.000 abstract description 3
- 230000003467 diminishing effect Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 3
- 231100000397 ulcer Toxicity 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 230000037257 muscle growth Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 12
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 6
- 150000001335 aliphatic alkanes Chemical class 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000399256 Pteromyini Species 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000003138 coordinated effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000301399 Trogopterus xanthipes Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZPHQBFRCXUIIAZ-UHFFFAOYSA-N benzene;hydrochloride Chemical compound Cl.C1=CC=CC=C1 ZPHQBFRCXUIIAZ-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种消肿止痛药膏,涉及外用药膏技术领域,为了解决现有药膏成分单一,难以去除病根的问题,包括以下原料:凡士林、红霉素、莫匹罗星、冰片、碘酊、甘油、月桂氮酮、盐酸普鲁卡因、盐酸苯海拉明、中药组合物,本发明还公开了所述消肿止痛药膏的制备方法,本发明制备的药膏外观细腻易涂布,稠度适中,耐热,耐寒,具有促进溃疡创面愈合以及消除脓肿的作用,以凡士林作为基质,让冰片充分发挥其止痛生肌作用,碘酊和红霉素抑菌消炎,并且通过加入中药配合使用,具有经通络、化痰散结、活血化瘀、消肿止痛的功效,西药与中药协同配合,消肿止痛效果更好,具有广阔的市场前景。
Description
技术领域
本发明涉及外用药膏技术领域,具体是一种消肿止痛药膏及其制备方法。
背景技术
凡在体表或某些粘膜部位应用,具有杀虫止痒、消肿散结、化腐排脓、生肌收口、收敛止血的一些药物,称为外用药。外用药主要用于痈疽疮毒、瘰疬、疥癣、外伤、蛇虫咬伤、烫伤及五官疾患等。根据其不同功用,可将外用药分为消肿解毒药、排脓祛腐药、止血生肌药、燥湿杀虫止痒药及发泡药5类。
药膏是人们常用的外用药,用于涂膜患处。
现有的药膏,其组分一般都只含有西药成分,成分单一,虽然见效快,但是难以从根本上去除病根,易反复。
发明内容
本发明的目的在于提供一种消肿止痛药膏及其制备方法,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种消肿止痛药膏,包括以下按照重量份的原料:凡士林10-20份、红霉素10-16份、莫匹罗星10-14份、冰片8-12份、碘酊2-6份、甘油6-12份、月桂氮酮5-9份、盐酸普鲁卡因6-10份、盐酸苯海拉明4-8份、中药组合物9-15份。
作为本发明进一步的方案:包括以下按照重量份的原料:凡士林12-18份、红霉素12-14份、莫匹罗星11-13份、冰片9-11份、碘酊3-5份、甘油8-10份、月桂氮酮6-8份、盐酸普鲁卡因7-9份、盐酸苯海拉明5-7份、中药组合物11-13份。
作为本发明进一步的方案:包括以下按照重量份的原料:凡士林15份、红霉素13份、莫匹罗星12份、冰片10份、碘酊4份、甘油9份、月桂氮酮7份、盐酸普鲁卡因8份、盐酸苯海拉明6份、中药组合物12份。
作为本发明进一步的方案:所述碘酊为1%碘酊。
作为本发明进一步的方案:所述中药组合物由天南星、忍冬藤、乳香、五灵脂和没药按照质量比比例为2:1:2:1:1组成。
作为本发明进一步的方案:所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
作为本发明进一步的方案:所述消肿止痛药膏的制备方法,步骤如下:
1)按配比称取各原料;
2)将冰片研磨成粉末,备用;
3)将中药组合物通过粉碎机充分粉碎,过120目筛;
4)将步骤2)得到的冰片粉末和步骤3)得到的中药粉末进行充分混合,然后与凡士林调匀;
5)将步骤4)得到的混合物中加入红霉素、莫匹罗星、冰片、碘酊、甘油、月桂氮酮、盐酸普鲁卡因、盐酸苯海拉明,充分搅匀,得到所需药膏。
碘有强大的杀菌作用,无论对真菌、原虫,还是对病毒、细菌芽孢都有效,局部使用效果直接、可靠,碘酊作为一种既有效,又经济且用途广泛的药物,当其直接作用于病灶时,微量酒精立即挥发,碘离子沉着并向基质层渗透,菌丝迅速受到破坏,病灶逐渐缩小,坏死组织脱落,胶原纤维增繁修复,使其瘢痕化或恢复一定的透明度。
红霉素属大环内酯类抗生素,对革兰氏阳性菌有较强抗菌活性,对某些革兰氏阴性菌及螺旋体、肺炎支原体、立克次氏体及衣原体等也有抑制作用,特别是用于葡萄球菌或链球菌感染的疾病,效果特别好。
冰片是中医药中一味常用佐药,中医认为其有开窍醒神、清热止痛、生肌之效;现代医学认为冰片有抗炎镇痛、抗菌、抗病毒、保护心脑、双向调节神经系统、提高其他药物生物利用等作用,且镇痛效应比抗炎效应更为明显;冰片可促进药物透过生物膜屏障以达到药物在机体内的最佳吸收、分布,在临床应用中能减少其他药物使用剂量,增加药物效应,减少药物毒、副作用;冰片性苦、微寒、性凉,自古就应用在中药配伍中治疗疾病,尤其对金黄色葡萄球菌等细菌有较强的抑菌作用,又以油剂的抗菌活性最强。
天南星为历史悠久的中药之一,能解毒消肿、祛风定惊、化痰散结。主治面神经麻痹、半身不遂、小儿惊风、破伤风、癫癎。外用治疗疮肿毒、毒蛇咬伤、灭蝇蛆。用胆汁处理过的称胆南星,主治小儿痰热、惊风抽搐。
五灵脂,中药材名。本品为鼯鼠科动物橙足鼯鼠和飞鼠等的干燥粪便。全年可采,但以春、秋为多,春采者品质较仕。采得后,拣净砂石、泥土等杂质,按形状分别为灵脂块和灵脂米两类。功能主治为:生用行血止痛。治心腹血气诸痛,妇女经闭,产后瘀血作痛;外治蛇、蝎、蜈蚣咬伤。
与现有技术相比,本发明的有益效果是:本发明制备的药膏外观细腻易涂布,稠度适中,耐热,耐寒,具有促进溃疡创面愈合以及消除脓肿的作用,以凡士林作为基质,让冰片充分发挥其止痛生肌作用,碘酊和红霉素抑菌消炎,并且通过加入中药配合使用,具有经通络、化痰散结、活血化瘀、消肿止痛的功效,西药与中药协同配合,消肿止痛效果更好,具有广阔的市场前景。
具体实施方式
下面将结合具体实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
本发明实施例中,一种消肿止痛药膏,包括以下按照重量份的原料:凡士林10份、红霉素10份、莫匹罗星10份、冰片8份、碘酊2份、甘油6份、月桂氮酮5份、盐酸普鲁卡因6份、盐酸苯海拉明4份、中药组合物9份。
其中,所述碘酊为1%碘酊。
所述中药组合物由天南星、忍冬藤、乳香、五灵脂和没药按照质量比比例为2:1:2:1:1组成。
所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
所述消肿止痛药膏的制备方法,步骤如下:
1)按配比称取各原料;
2)将冰片研磨成粉末,备用;
3)将中药组合物通过粉碎机充分粉碎,过120目筛;
4)将步骤2)得到的冰片粉末和步骤3)得到的中药粉末进行充分混合,然后与凡士林调匀;
5)将步骤4)得到的混合物中加入红霉素、莫匹罗星、冰片、碘酊、甘油、月桂氮酮、盐酸普鲁卡因、盐酸苯海拉明,充分搅匀,得到所需药膏。
实施例2
本发明实施例中,一种消肿止痛药膏,包括以下按照重量份的原料:凡士林12份、红霉素12份、莫匹罗星11份、冰片9份、碘酊3份、甘油8份、月桂氮酮6份、盐酸普鲁卡因7份、盐酸苯海拉明5份、中药组合物11份。
其中,所述碘酊为1%碘酊。
所述中药组合物由天南星、忍冬藤、乳香、五灵脂和没药按照质量比比例为2:1:2:1:1组成。
所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
所述消肿止痛药膏的制备方法,步骤如下:
1)按配比称取各原料;
2)将冰片研磨成粉末,备用;
3)将中药组合物通过粉碎机充分粉碎,过120目筛;
4)将步骤2)得到的冰片粉末和步骤3)得到的中药粉末进行充分混合,然后与凡士林调匀;
5)将步骤4)得到的混合物中加入红霉素、莫匹罗星、冰片、碘酊、甘油、月桂氮酮、盐酸普鲁卡因、盐酸苯海拉明,充分搅匀,得到所需药膏。
实施例3
本发明实施例中,一种消肿止痛药膏,包括以下按照重量份的原料:凡士林15份、红霉素13份、莫匹罗星12份、冰片10份、碘酊4份、甘油9份、月桂氮酮7份、盐酸普鲁卡因8份、盐酸苯海拉明6份、中药组合物12份。
其中,所述碘酊为1%碘酊。
所述中药组合物由天南星、忍冬藤、乳香、五灵脂和没药按照质量比比例为2:1:2:1:1组成。
所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
所述消肿止痛药膏的制备方法,步骤如下:
1)按配比称取各原料;
2)将冰片研磨成粉末,备用;
3)将中药组合物通过粉碎机充分粉碎,过120目筛;
4)将步骤2)得到的冰片粉末和步骤3)得到的中药粉末进行充分混合,然后与凡士林调匀;
5)将步骤4)得到的混合物中加入红霉素、莫匹罗星、冰片、碘酊、甘油、月桂氮酮、盐酸普鲁卡因、盐酸苯海拉明,充分搅匀,得到所需药膏。
实施例4
本发明实施例中,一种消肿止痛药膏,包括以下按照重量份的原料:凡士林18份、红霉素14份、莫匹罗星13份、冰片11份、碘酊5份、甘油10份、月桂氮酮8份、盐酸普鲁卡因9份、盐酸苯海拉明7份、中药组合物13份。
其中,所述碘酊为1%碘酊。
所述中药组合物由天南星、忍冬藤、乳香、五灵脂和没药按照质量比比例为2:1:2:1:1组成。
所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
所述消肿止痛药膏的制备方法,步骤如下:
1)按配比称取各原料;
2)将冰片研磨成粉末,备用;
3)将中药组合物通过粉碎机充分粉碎,过120目筛;
4)将步骤2)得到的冰片粉末和步骤3)得到的中药粉末进行充分混合,然后与凡士林调匀;
5)将步骤4)得到的混合物中加入红霉素、莫匹罗星、冰片、碘酊、甘油、月桂氮酮、盐酸普鲁卡因、盐酸苯海拉明,充分搅匀,得到所需药膏。
实施例5
本发明实施例中,一种消肿止痛药膏,包括以下按照重量份的原料:凡士林20份、红霉素16份、莫匹罗星14份、冰片12份、碘酊6份、甘油12份、月桂氮酮9份、盐酸普鲁卡因10份、盐酸苯海拉明8份、中药组合物15份。
其中,所述碘酊为1%碘酊。
所述中药组合物由天南星、忍冬藤、乳香、五灵脂和没药按照质量比比例为2:1:2:1:1组成。
所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
所述消肿止痛药膏的制备方法,步骤如下:
1)按配比称取各原料;
2)将冰片研磨成粉末,备用;
3)将中药组合物通过粉碎机充分粉碎,过120目筛;
4)将步骤2)得到的冰片粉末和步骤3)得到的中药粉末进行充分混合,然后与凡士林调匀;
5)将步骤4)得到的混合物中加入红霉素、莫匹罗星、冰片、碘酊、甘油、月桂氮酮、盐酸普鲁卡因、盐酸苯海拉明,充分搅匀,得到所需药膏。
对比例1
与实施例3相比,不含莫匹罗星,其他与实施例3相同。
对比例2
与实施例3相比,不含天南星,其他与实施例3相同。
对比例3
与实施例3相比,不含莫匹罗星和天南星,其他与实施例3相同。
性能验证
选取400名外科病人,其由于各种原因造成皮肤溃疡创面并且出现肿块,将200名病人均分为4组。
治疗方法:将消肿止痛药膏均匀涂抹于纱布上,约2毫米厚度,其范围略大于疼痛及肿块面积,贴敷于患处。
治疗时间:2周为一疗程,根据病情治疗1~3个疗程。
治疗效果标准:
显效:疼痛消失,肿块消退;
有效:疼痛明显减轻,肿块消退1/2以上;
无效:疼痛未减轻,肿块无变化。
统计治疗效果,如下表1所示:
| 组别 | 有效/例 | 显效/例 | 无效/例 | 无效率/% | 有效率/% |
| 对比例1 | 75 | 18 | 7 | 7 | 93 |
| 对比例2 | 76 | 17 | 7 | 7 | 93 |
| 对比例3 | 61 | 10 | 19 | 19 | 81 |
| 实施例3 | 82 | 19 | 0 | 0 | 100 |
从以上结果可以看出,本发明制备的药膏能够消肿止痛,尤其是通过天南星和莫匹罗星的协同增效作用,本发明制备的药膏外观细腻易涂布,稠度适中,耐热,耐寒,具有促进溃疡创面愈合以及消除脓肿的作用,以凡士林作为基质,让冰片充分发挥其止痛生肌作用,碘酊和红霉素抑菌消炎,并且通过加入中药配合使用,具有经通络、化痰散结、活血化瘀、消肿止痛的功效,西药与中药协同配合,消肿止痛效果更好,具有广阔的市场前景。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (8)
1.一种消肿止痛药膏,其特征在于,包括以下按照重量份的原料:凡士林10-20份、红霉素10-16份、莫匹罗星10-14份、冰片8-12份、碘酊2-6份、甘油6-12份、月桂氮酮5-9份、盐酸普鲁卡因6-10份、盐酸苯海拉明4-8份、中药组合物9-15份。
2.根据权利要求1所述的消肿止痛药膏,其特征在于,包括以下按照重量份的原料:凡士林12-18份、红霉素12-14份、莫匹罗星11-13份、冰片9-11份、碘酊3-5份、甘油8-10份、月桂氮酮6-8份、盐酸普鲁卡因7-9份、盐酸苯海拉明5-7份、中药组合物11-13份。
3.根据权利要求2所述的消肿止痛药膏,其特征在于,包括以下按照重量份的原料:凡士林15份、红霉素13份、莫匹罗星12份、冰片10份、碘酊4份、甘油9份、月桂氮酮7份、盐酸普鲁卡因8份、盐酸苯海拉明6份、中药组合物12份。
4.根据权利要求1所述的消肿止痛药膏,其特征在于,所述碘酊为1%碘酊。
5.根据权利要求1所述的消肿止痛药膏,其特征在于,所述中药组合物由天南星、忍冬藤、乳香、五灵脂和没药按照质量比比例为2:1:2:1:1组成。
6.根据权利要求1所述的消肿止痛药膏,其特征在于,所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
7.如权利要求1-6任一所述的消肿止痛药膏的制备方法,其特征在于,步骤如下:
1)按配比称取各原料;
2)将冰片研磨成粉末,备用;
3)将中药组合物通过粉碎机充分粉碎,过120目筛;
4)将步骤2)得到的冰片粉末和步骤3)得到的中药粉末进行充分混合,然后与凡士林调匀;
5)将步骤4)得到的混合物中加入红霉素、莫匹罗星、冰片、碘酊、甘油、月桂氮酮、盐酸普鲁卡因、盐酸苯海拉明,充分搅匀,得到所需药膏。
8.如权利要求1-6任一所述的消肿止痛药膏在制备消肿止痛外用产品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811268843.4A CN109091584A (zh) | 2018-10-29 | 2018-10-29 | 一种消肿止痛药膏及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811268843.4A CN109091584A (zh) | 2018-10-29 | 2018-10-29 | 一种消肿止痛药膏及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109091584A true CN109091584A (zh) | 2018-12-28 |
Family
ID=64869590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811268843.4A Withdrawn CN109091584A (zh) | 2018-10-29 | 2018-10-29 | 一种消肿止痛药膏及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109091584A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353892A (zh) * | 2020-11-30 | 2021-02-12 | 新疆畜牧科学院畜牧研究所 | 一种治疗驴皮肤病、促伤口愈合的药物配方及其制备方法 |
| CN114632139A (zh) * | 2022-04-02 | 2022-06-17 | 北京双吉制药有限公司 | 一种红霉素药膏及其制备方法 |
-
2018
- 2018-10-29 CN CN201811268843.4A patent/CN109091584A/zh not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353892A (zh) * | 2020-11-30 | 2021-02-12 | 新疆畜牧科学院畜牧研究所 | 一种治疗驴皮肤病、促伤口愈合的药物配方及其制备方法 |
| CN114632139A (zh) * | 2022-04-02 | 2022-06-17 | 北京双吉制药有限公司 | 一种红霉素药膏及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101537107A (zh) | 有效治疗皮肤真菌病的外用擦剂及其制备方法 | |
| CN104415265A (zh) | 一种治疗灰指甲的药膏及其制备方法 | |
| CN109091584A (zh) | 一种消肿止痛药膏及其制备方法 | |
| CN105662996A (zh) | 治疗月经相关性痤疮的中药面膜 | |
| CN111067971A (zh) | 一种治疗甲沟炎的中药组合物及其使用方法 | |
| CN103751309A (zh) | 一种治疗肋间神经痛的中药外用制剂及其制备方法 | |
| CN103585263B (zh) | 一种治疗慢性化脓性中耳炎的中药组合物及其制备方法 | |
| CN104623554A (zh) | 用于改善下肢切口愈合情况的祛腐生肌散 | |
| CN103585330B (zh) | 一种用于皮肤真菌感染的中药组合物及其制备方法 | |
| CN105327244A (zh) | 一种含有艾叶的治疗褥疮的中药组合物及其制备方法 | |
| CN111773341A (zh) | 一种治疗仔猪疥癣病的复方中草药外用制剂 | |
| CN106728069B (zh) | 一种治疗烫烧伤的祛腐生肌膏 | |
| CN105169183A (zh) | 一种治疗褥疮的中药组合物及其制备方法 | |
| CN104623443A (zh) | 治疗皮肤糜烂的中药 | |
| CN112294922A (zh) | 一种治疗阴道炎的中草药物及其制作方法 | |
| CN103550510A (zh) | 一种用于治疗各类阴道炎的洗剂 | |
| CN108114029A (zh) | 一种中药活性物组合物、其制备方法及其应用 | |
| CN101112531A (zh) | 一种具有抗生素功效的中药外用乳浊液制剂及其制备方法 | |
| CN107617009B (zh) | 一种治疗家兔皮肤毛囊炎的复方中草药外用制剂 | |
| CN111743965A (zh) | 一种以再生硅治疗痔疮和溃疡的药物 | |
| CN1050753C (zh) | 创口愈合剂 | |
| CN1204912C (zh) | 治疗烧烫伤、软组织损伤和皮肤病的外用药剂 | |
| CN121401339A (zh) | 一种促进创面愈合的组合物及其制备方法与应用 | |
| CN1969996A (zh) | 一种止血定痛消肿生肌的中药散剂及其配制方法 | |
| CN104998023B (zh) | 一种用于治疗痤疮、疖肿的药物组合物及药膏 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181228 |
|
| WW01 | Invention patent application withdrawn after publication |